- As of June 29, 2026, 4DMedical's CT:VQ has received regulatory clearance in six major markets: the United States, European Union, United Kingdom, Canada, New Zealand, and now Australia.
- Australia ranks second globally in CT scanner density at 74+ units per million people, giving the company a well-equipped home market for rapid commercial rollout.
- Revenue reached AU$5.86 million over the past 12 months—a 471% year-over-year increase—though profitability is still ahead, with analyst projections ranging from AU$350,000 to AU$6.50 million for full-year 2026.
- Despite the positive regulatory news, 4DMedical's stock fell 10.7% to AU$4.08 on June 26, 2026—a counterintuitive move that says more about valuation than about the technology's prospects.
What Happened
Picture a patient with unexplained breathlessness lying inside a CT scanner. The scan takes about 90 seconds. Under the traditional diagnostic workflow, assessing how air and blood actually move through that patient's lungs required a completely separate appointment in a nuclear medicine suite—radioactive tracers injected, a specialized gamma camera, and 45 to 90 minutes of waiting while the tracers mapped pulmonary function. Now, a software platform can extract that same functional information automatically from the routine CT scan the patient already had, with no tracers, no extra equipment, and no second visit.
That is the clinical proposition behind CT:VQ, and on June 28–29, 2026, Australia's Therapeutic Goods Administration (TGA)—the federal regulator for medical devices in Australia, roughly equivalent to the US FDA—granted commercial deployment approval for the technology. According to reporting aggregated by Google News, the clearance enables 4DMedical to begin selling CT:VQ commercially across Australian hospitals and imaging centers for the first time.
The TGA milestone brings 4DMedical's total regulatory clearances to six major markets. The US FDA granted 510(k) clearance in September 2025. The European Union, United Kingdom, Canada, and New Zealand followed. Australia—the company's home country—is the sixth.
The Evidence Tier — What Six Regulatory Clearances Actually Signal
Regulatory clearances confirm that a device meets a defined safety and performance threshold. They do not guarantee clinical superiority over every existing alternative, and it's worth holding that distinction in mind before drawing conclusions about the investment case. That said, the deployment data accumulating behind those clearances is directionally encouraging.
Following FDA clearance in September 2025, the US Centers for Medicare & Medicaid Services confirmed Medicare reimbursement for CT:VQ under Category III CPT codes—billing codes specifically designed to allow payment for emerging technologies while long-term outcome data accumulates. That reimbursement pathway matters enormously: without it, hospitals can use the technology but struggle to bill for it routinely. As of June 29, 2026, active US deployment sites include Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, University of Miami, and SimonMed, the largest private outpatient radiology network in the United States. The installed base of CT scanners eligible for CT:VQ in the US alone is approximately 14,500 units.
4DMedical CEO and founder Andreas Fouras framed the Australian opportunity in terms of infrastructure: "Australia's high CT scanner density makes an attractive market for broad implementation," he noted following the TGA announcement, describing the clearance as "an important milestone for respiratory diagnostics in our home market." With more than 74 CT units per million people, Australia sits second globally—behind only Japan's approximately 120 per million—meaning the hardware substrate for broad CT:VQ adoption already exists across the country's hospital and imaging network.
The revenue numbers validate that deployments are converting to commercial activity. As of June 29, 2026, 4DMedical reported AU$5.86 million in revenue over the trailing 12 months, a 471% year-over-year increase. Half-to-half revenue growth stood at 16.5%, deployment sites expanded 24%, and total scan volume climbed 37%. These metrics are moving in consistent direction rather than isolated spikes—a meaningful distinction when evaluating early-stage growth companies.
Chart: The pulmonary embolism diagnostics market—where CT:VQ has its most immediate application—is projected to grow from US$2.15 billion in 2024 to US$4.78 billion by 2034 at an 8.32% compound annual growth rate. Source: research data cited in 4DMedical coverage, as of June 29, 2026.
Why the Stock Dropped 10% on a Positive Milestone
4DMedical's stock fell 10.7% to AU$4.08 on June 26, 2026, the day surrounding the TGA announcement—and for investors new to growth stocks, a falling price on good news is one of the most disorienting experiences in the stock market today. The mechanics behind it are worth understanding before acting.
Several dynamics were likely at work simultaneously. "Buy the rumor, sell the news" is a well-documented pattern in markets: sophisticated investors position ahead of an anticipated event, then exit when confirmation arrives. The TGA approval, while genuinely meaningful, was also highly predictable—five other major regulators had already cleared the device, and Australia was the logical next step. Beyond that, at a market capitalization near AU$2.7 billion against AU$5.86 million in trailing revenue, the stock price already reflected enormous optimism about future commercial scale. A regulatory confirmation does not move that needle the way a surprise contract win or an unexpected profitability inflection would. What actually re-rates high-multiple growth stocks is evidence that the pace of execution is faster than the market's already-elevated baseline assumption.
None of that means the underlying thesis is impaired. It means that at AU$2.7 billion in market cap, the stock is doing what efficiently priced growth equities do: requiring continuous positive surprises just to stay flat.
The AI Architecture Driving the Platform
CT:VQ is not a simple image overlay. It uses advanced mathematical models to analyze the subtle motion and density changes in lung tissue across frames of a non-contrast chest CT, automatically generating quantitative maps of ventilation (airflow through airways) and perfusion (blood flow through pulmonary vessels)—the two functional measurements that nuclear medicine scans have traditionally been required to provide. The clinical output arrives without human intervention and without exposing patients to radioactive tracers.
4DMedical has systematically expanded this AI foundation through targeted acquisitions. In 2023, the company acquired US-based Imbio for up to US$68.4 million, adding AI-driven cardiothoracic scanning capabilities across a wider set of CT-based diagnoses. In 2026, it acquired Austria-based contextflow GmbH for approximately €11.4 million in cash plus 56,235 shares, bringing a CE-marked AI suite for lung cancer detection and clinical decision support already embedded in European hospital workflows. The result is less a single-product company and more an AI-first respiratory diagnostics platform delivering multiple tools through a software-as-a-service architecture built on top of hardware infrastructure hospitals already own. (That deployment model—AI as an intelligent layer on existing compute substrate—mirrors the pattern reshaping many industries where the hardware is already in place and the value is in the software that reads it.)
To fund continued US expansion, 4DMedical completed a US$100 million-plus institutional placement in January 2026, bringing its pro forma cash position above AU$200 million. Strategic validators include a US$10 million minimum order commitment from Philips Healthcare spanning December 2025 through 2027, and a AU$10 million strategic investment from Pro Medicus—a well-regarded ASX-listed radiology software company—in August 2025. Fouras has described 2026 as "a defining year" as the company works to establish CT:VQ as the global standard for functional lung assessment, a framing the regulatory momentum is beginning to support.
What Investors Should Actually Do With This Information
The pulmonary embolism diagnostics market—where CT:VQ has its most immediate clinical application—was valued at US$2.15 billion in 2024 and is projected to reach US$4.78 billion by 2034, growing at an 8.32% CAGR (compound annual growth rate: the average annual growth needed to reach the projected endpoint over the period). That is a real and sizable addressable opportunity, and 4DMedical's current positioning across six markets, with US Medicare reimbursement secured and top-tier health systems as early adopters, is genuinely differentiated.
The open question for any investment portfolio is what that positioning is worth at today's price. At AU$2.7 billion market cap against AU$5.86 million in trailing revenue, the stock prices in transformative commercial scale that has not yet arrived. Analysts project first profitability somewhere between AU$350,000 and AU$6.50 million in 2026—a wide range that signals genuine uncertainty about the pace of revenue conversion as new markets open.
In my analysis, the most consequential near-term event following TGA clearance is not the clearance itself—it is whether 4DMedical can secure a Medicare Benefits Schedule (MBS) listing in Australia. The MBS is Australia's public health billing system; without an MBS listing, even a TGA-approved device faces significant friction in generating consistent revenue from the majority public-hospital sector. The company has flagged an MBS application as the planned next step, but no timeline was disclosed as of June 29, 2026. That filing date and outcome should be the milestone investors track, not the TGA announcement that has already been priced in.
When I look at the full picture—471% revenue growth, six-market regulatory clearance in under 18 months, strategic backing from Philips and Pro Medicus, and a US footprint anchored by some of the most analytically rigorous health systems in the world—the operational momentum is real. The financial planning question is whether AU$2.7 billion is the right entry price for that momentum, or whether waiting for an MBS listing or a profitability inflection represents a more considered approach for a diversified portfolio.
TGA approval permits commercial sales in Australia; an MBS listing enables routine billing under the country's public health system. Without it, CT:VQ's Australian revenue is limited to private imaging networks. This is the next material commercial catalyst in 4DMedical's home market—watch company announcements for an MBS filing date and government response timeline, as this event will likely matter more to Australian revenue than the TGA clearance itself.
Deployment sites growing 24% and scan volume climbing 37% are both encouraging signals, but the metric that matters for investment portfolio evaluation is revenue translating from those scans. The most recent data shows AU$5.86 million across 12 months with 16.5% half-to-half revenue growth. Watch whether that growth rate accelerates—particularly in the US, where Medicare reimbursement under Category III CPT codes is now in place and deployment sites include high-volume institutions like SimonMed's nationwide outpatient network.
At AU$2.7 billion market cap and AU$5.86 million in trailing revenue, 4DMedical is priced as a future market leader, not a current earner. For personal finance purposes, this profile fits best in a portfolio's higher-risk growth allocation—alongside other pre-profit AI medtech companies—rather than as a core position. The stock's 10.7% decline on positive regulatory news is a useful reminder: at high multiples, execution must be consistently ahead of already-elevated expectations just to maintain the current price.
Frequently Asked Questions
How does a CT VQ scan work without radioactive tracers or contrast agents?
CT:VQ uses advanced mathematical algorithms to analyze the subtle motion and density changes in lung tissue captured across frames of a standard, non-contrast chest CT scan. By tracking how air moves through airways (ventilation) and how blood flows through pulmonary vessels (perfusion), the software automatically generates quantitative maps of both functions. The patient undergoes a routine CT scan; the AI platform extracts the functional lung data from that existing scan. No radioactive tracers are injected, no specialized gamma camera is required, and the 45-to-90-minute nuclear medicine procedure is eliminated entirely.
What does TGA approval mean for medical devices in Australia?
Australia's Therapeutic Goods Administration is the federal regulator for medicines and medical devices—broadly equivalent to the US FDA or the UK's MHRA. TGA approval means the device has met Australian safety and performance standards and can be legally marketed and sold commercially across the country. Without it, a company can conduct clinical research in Australia but cannot generate routine commercial revenue. As of June 29, 2026, the TGA clearance opens full commercial deployment for CT:VQ across Australian hospitals and imaging centers and sets the stage for 4DMedical's subsequent Medicare Benefits Schedule reimbursement application.
Is CT:VQ imaging more accurate than a traditional nuclear medicine VQ scan?
The clinical comparison is still accumulating. Traditional nuclear medicine V/Q scans have decades of validated diagnostic use and broad insurance coverage. CT:VQ offers potential advantages in speed—standard CT duration versus 45 to 90 minutes for nuclear V/Q—and in availability, since CT scanners vastly outnumber nuclear medicine suites (approximately 14,500 in the US alone). Regulatory clearances in six markets confirm safety and efficacy thresholds have been met, but head-to-head accuracy data across diverse patient populations and indications is still being generated as deployments expand at institutions like Stanford, Cleveland Clinic, and UC San Diego Health.
Is 4DMedical stock a good investment after the TGA approval?
This post does not constitute financial advice—anyone considering a position should speak with a licensed financial advisor. What publicly available data shows as of June 29, 2026: 4DMedical has 471% year-over-year revenue growth, six-market regulatory clearance, US Medicare reimbursement secured, and strategic backing from Philips Healthcare and Pro Medicus. It also carries a market capitalization near AU$2.7 billion against AU$5.86 million in trailing revenue—a very high price-to-sales multiple that reflects anticipated future growth, not current earnings. The stock's 10.7% decline on announcement day is a signal that the market had already priced in the TGA outcome well before it was confirmed.
Disclaimer: This article is editorial commentary for informational and educational purposes only. It does not constitute financial, investment, or medical advice. All figures are sourced from publicly reported data and have not been independently audited or verified. Research based on publicly available sources current as of June 29, 2026.